API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/08/30/2734776/0/en/PLOS-ONE-Publishes-Data-on-Allarity-Therapeutics-DRP-Companion-Diagnostic-for-Dovitinib.html
https://www.globenewswire.com/news-release/2023/03/20/2630044/0/en/Allarity-Therapeutics-Doses-First-Patient-in-Phase-1b-Clinical-Trial-Evaluating-Dovitinib-and-Stenoparib-Combination-in-Advanced-Solid-Tumors.html
https://www.fiercebiotech.com/biotech/forced-clarity-allarity-loses-hope-lead-asset-restructures-pipeline-after-fda-meeting
http://www.pharmafile.com/news/588506/allarity-therapeutics-partners-lonza-manufacture-dovitinib
https://www.globenewswire.com/news-release/2021/09/16/2298130/0/en/Allarity-Therapeutics-Presents-Dovitinib-Survival-Data-from-DRP-Screened-RCC-Patients-at-ESMO-2021-Virtual-Congress.html
https://www.globenewswire.com/news-release/2021/07/05/2257841/0/en/Allarity-Therapeutics-Receives-Acceptance-Review-Notification-from-U-S-FDA-for-Pre-Market-Approval-Application-for-Dovitinib-DRP.html
https://www.globenewswire.com/news-release/2021/06/14/2246403/0/en/Allarity-Therapeutics-and-Oncoheroes-Biosciences-to-Partner-on-Pediatric-Cancer-Development-of-Dovitinib-and-Stenoparib.html
https://www.globenewswire.com/news-release/2020/10/23/2113411/0/en/Allarity-Therapeutics-Provides-Update-on-Dovitinib-Program.html#:~:text=The%20Company%20is%20announcing%20an,renal%20cell%20carcinoma%20(RCC).&text=A%20registration%20batch%20is%20a,file%20the%20NDA%20in%202021.
https://www.globenewswire.com/news-release/2020/06/08/2045170/0/en/Press-release-Oncology-Venture-acquires-full-control-of-Dovitinib-program.html#:~:text=Hoersholm%2C%20Denmark%20(8%20June%202020,from%20investor%20Sass%20%26%20Larsen%20ApS.
https://globenewswire.com/news-release/2019/02/07/1712072/0/en/Clinical-update-Dovitinib-DRP-data-mining-successfully-completed-and-new-LiPlaCis-data-continues-to-support-an-FDA-breakthrough-designation-strategy.html
https://www.fiercebiotech.com/biotech/novartis-farms-out-rare-disease-drug-to-lifemax-labs
https://endpts.com/biotech-resurrects-a-long-faded-novartis-cancer-drug-star-using-a-biomarker-strategy-to-push-ahead/